Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.
OncLive TV
Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms
Advertisement
Dr. Raoul Concepcion, from Urology Associates, PC, Discusses Urologists Treating Cancer.
Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate
Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T
Paul Jacobsen, from H. Lee Moffitt Cancer Center and Research Institute, Discusses Cancer Survivorship Rehabilitation.
Advertisement
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.
Dr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.
Donna Berry, from Dana-Farber Cancer Institute, on Compliance to Oral Cancer Therapies.
Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.
Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.
Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel
Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival
Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints
Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.
Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action
Dr. Diane Bodurka, from the MD Anderson Cancer Center, on the Increasing Number of Cancer Surivors
Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.
Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.
Dr. Richard Schilsky, from the University of Chicago, Summarizes the Recent Oncology Drug Shortage.
Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.
Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer
Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer
Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.
Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.
Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
Dr. Raoul Concepcion, from the Urology Associates, PC, Nashville, TN, on Bladder Cancer Treatment and Costs.
Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5